URCE: Biocontrol Technology, Inc.
Biocontrol Diasense Subsidiary to Market Diasensor on the Internet
PITTSBURGH, Aug. 5 /PRNewswire/ -- Biocontrol Technology, Inc. (Nasdaq: BICO - news) subsidiary Diasense, Inc.
today announced marketing plans for the Diasensor(R)1000, the world's first noninvasive glucose sensor, which recently
received European marketing approval. Diasense plans to penetrate international markets by aggressive Internet marketing,
licensing the Diasensor technology, entering into joint venture agreements to market and/or manufacture the sensor, and by
establishing exclusive distributors. Initial focus will be on the 15-member European Union (EU), with a market of 30
million people with diabetes. The Diasensor's market entry price will be US$9,000.
In addition, Diasense will proceed with other markets outside the EU with large diabetic populations where the CE Mark is
not required but is looked to for medical devices. For example, India, Saudi Arabia, United Arab Emirates, and Pakistan
combined account for approximately 26,500,000 diabetics.
Because the Diasensor is the first noninvasive glucose sensor to ever be made commercially available to the diabetic
population, Diasense will also work to educate and establish a network of clinicians, health care professionals, and diabetic
associations in each country.
Biocontrol Technology, Inc. (www.bico.com) has its corporate offices in Pittsburgh, PA, and is involved in the
development and manufacture of biomedical devices and environmental products. Also located in Pittsburgh, PA, Diasense
is a subsidiary of Biocontrol Technology and owns the patent, marketing and distribution rights to the sensor. Biocontrol
has the exclusive rights to the research and development and manufacturing of the sensor.
This press release contains forward looking statements and shareholders and potential investors are cautioned that such
statements are predictions and actual events or results may vary significantly.
SOURCE: Biocontrol Technology, Inc.
More Quotes and News:
Biocontrol Technology Inc (Nasdaq:BICO - news)
Related News Categories: internet, medical/pharmaceutical |
